Highly Purified Eicosapentaenoic Acid Improves Decreased Toe-Brachial Index in Japanese Patients with Type 2 Diabetes Mellitus

Hiroyuki Shimizu*

Department of Diabetes and Endocrinology, International University of Health and Welfare (IUHW) Hospital, Nasushiobara, Japan

Abstract

Eicosapentaenoic acid (EPA), which is an important polyunsaturated fatty acid in fish oil, improves blood coagulability and prevents thrombosis. EPA is usually available for treatment of patients with obliterating arteriosclerosis in Japan, but its usefulness for microcirculation in the foot has not been established. We studied the effect of highly purified ethyl eicosapentaenoate on decreased microcirculation in the foot in Japanese patients with type 2 diabetes mellitus. Changes in ankle-brachial index (ABI), toe systolic pressure, and toe-brachial index (TBI) with administration of EPA were evaluated in outpatients. Individual comparison of mean values before and after treatment was performed by using paired Student t test. Both decreased toe systolic pressure and TBI significantly improved with administration of ethyl eicosapentaenoate for 4 weeks in patients who had decreased TBI; decreased TBI was normalized in 24 of 35 big toes (68.6%). In addition, treatment improved decreased ABI; decreased ABI was normalized in 4 of 6 lower limbs (66.7%). This study confirmed that administration of highly purified ethyl eicosapentaenoate improves peripheral microcirculation in diabetic patients with decreased TBI and ABI.

Keywords: Toe-Brachial Index (TBI); Ankle-Brachial Index (ABI); Eicosapentaenoic acid; Type 2 diabetes mellitus; Peripheral artery disease

Introduction

Disturbance of peripheral microcirculation in the lower limbs of diabetic patients is associated with skin ulcer and/or foot gangrene [1]. A diagnosis of Peripheral Artery Disease (PAD) indicates a high risk of amputation in diabetic patients, but amputation of a lower limb worsens the quality of life of these patients. Improved peripheral microcirculation in the foot should effectively prevent the risk of amputation.

Fish oil, which is rich in n-3 Polyunsaturated Fatty Acid (PUFA), contains a property that prevents the development of atherosclerosis and thrombosis [2]. Dietary supplementation with n-3 PUFA has been reported to improve decreased Ankle-Brachial Index (ABI) in patients with PAD [3]. Eicosapentaenoic acid (EPA), which is an important PUFA in fish oil, improves blood coagulability and prevents the development of thrombosis [4]. The ratio of plasma EPA to Arachidonic Acid (AA) has been reported to be significantly decreased in patients with PAD, indicating that a reduced ratio of plasma EPA/AA may be involved in the development of peripheral arteriosclerosis in these patients [5]. Highly purified EPA has been reported to significantly reduce brachial-ankle pulse wave velocity in patients with cardiovascular risk factors [6] or Type 2 Diabetes Mellitus (T2DM) [7]. However, whether highly purified EPA improves peripheral microcirculation in the toes of diabetic patients with obliterating arteriosclerosis has not yet been investigated. The present data demonstrate a possible improvement of peripheral microcirculation in the toes of diabetic patients with obliterating arteriosclerosis because the range of normal TBI values is greater than 0.6 [8].

EPA is well confirmed to be clinically available for the treatment of patients with obliterating arteriosclerosis in Japan. After the patients provided consent, highly purified ethyl eicosapentaenoate (Mochida Pharmaceuticals Co. Ltd., Tokyo, Japan) was prescribed at a dosage of 900 mg twice a day (a total of 1800 mg/day). The purity of ethyl eicosapentaenoate is greater than 98%. The patients were treated with ethyl eicosapentaenoate over 4 weeks.

Measurement

ABI, Toe Systolic Pressure (TSB), and TBI were measured with the patient in a supine position on a bed by using the Forum ABI/PWV (Omron Colin Co., Ltd., Tokyo, Japan) [9]. TSB was measured in both big toes in each patient. ABI was calculated by dividing calf systolic blood pressure by brachial systolic blood pressure, and TBI was calculated by dividing big toe systolic
Highly Purified Eicosapentaenoic Acid Improves Decreased Toe-Brachial Index in Japanese Patients with Type 2 Diabetes Mellitus

blood pressure by brachial systolic blood pressure. TBI, TSB, and ABI were measured before and 4 weeks after the start of treatment with EPA, and the effects of ethyl eicosapentaenoate were evaluated by measuring TBI, TSB, and ABI.

Statistical analysis

All data are expressed as mean ± SD. Statistical analysis was performed by using Prism Version 4.0b computer software. Individual comparison of the mean values before and after treatment was performed by using paired Student t test. P < 0.05 was considered statistically significant.

Results

After treatment with ethyl eicosapentaenoate for 4 weeks, 10 patients had a significant decrease in TBI of both the right and left big toes and 15 patients had a significant decrease in TBI of only a single big toe (right or left). As shown in Table 1, body weight and glycemic control did not change as a result of treatment. Decreased TSB with decreased blood flow in the big toes of these patients significantly increased from 72.8 mm Hg to 87.8 mm Hg, although brachial systolic and diastolic blood pressure did not change. Decreased TBI significantly improved from 0.48 to 0.61 and was normalized in 24 of 35 big toes (68.6%). In addition, ABI significantly increased from 1.09 to 1.13. Although the ABI was less than 0.9 in 6 of 35 lower limbs (17.1%) in the 35 patients with T2DM who have decreased ABI before the start of the treatment, the decreased ABI normalized in 4 of these 6 lower limbs (66.7%).

Discussion

This study showed that administration of highly purified ethyl eicosapentaenoate for 4 weeks significantly improved decreased TSB and TBI in Japanese patients with T2DM, independently of glycemic control and brachial systolic blood pressure. TSB and TBI significantly improved from 72.8 mm Hg to 87.8 mm Hg, although brachial systolic and diastolic blood pressure did not change. Decreased TBI significantly improved from 0.48 to 0.61 and was normalized in 24 of 35 big toes (68.6%). In addition, ABI significantly increased from 1.09 to 1.13. Although the ABI was less than 0.9 in 6 of 35 lower limbs (17.1%) in the 35 patients with T2DM who have decreased ABI before the start of the treatment, the decreased ABI normalized in 4 of these 6 lower limbs (66.7%).

Table 1: Changes of metabolic parameters before and at 4 weeks after the high purity ethyl eicosapentaenoate administration.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>before</th>
<th>4 weeks</th>
</tr>
</thead>
<tbody>
<tr>
<td>Body weight (kg)</td>
<td>64.3 ± 1.7</td>
<td>63.7 ± 1.6</td>
</tr>
<tr>
<td>Blood glucose (mg/dl)</td>
<td>170.2 ± 14.4</td>
<td>174.1 ± 11.3</td>
</tr>
<tr>
<td>HbA1c (%)</td>
<td>7.75 ± 0.34</td>
<td>7.59 ± 0.31</td>
</tr>
<tr>
<td>BP (mmHg)</td>
<td>135.6 ± 3.2</td>
<td>138.8 ± 2.7</td>
</tr>
<tr>
<td>DBP (mmHg)</td>
<td>76.8 ± 2.3</td>
<td>79.6 ± 1.9</td>
</tr>
<tr>
<td>TSB (mmHg)</td>
<td>72.8 ± 8.5</td>
<td>87.8 ± 6.1 **</td>
</tr>
<tr>
<td>TBI</td>
<td>0.48 ± 0.03</td>
<td>0.61 ± 0.02 **</td>
</tr>
<tr>
<td>ABI</td>
<td>1.09 ± 0.03</td>
<td>1.13 ± 0.02 *</td>
</tr>
</tbody>
</table>

*p < 0.05; ** p < 0.01 vs. the value before the start of high purity EPA administration. Data represent mean ± SD. SBP: Systolic Blood Pressure, DBP: Diastolic Blood Pressure.

The EPA/AA ratio has been reported to be significantly lower in patients with PAD [6], but administration of highly purified ethyl eicosapentaenoate significantly increases this ratio [10]. We have previously demonstrated a significant reduction of plasma thrombin-antithrombin III complex with administration of ethyl eicosapentaenoate for 4 weeks in patients with T2DM who have albuminuria [11]. The present data showed that the effect of ethyl eicosapentaenoate on peripheral circulation in the toes is apparent after only 4 weeks of treatment. Therefore, an improvement in hypercoagulability with use of highly purified ethyl eicosapentaenoate contributes to improvement of peripheral circulation in big toes. Furthermore, the Japan EPA Lipid Intervention Study (JELIS) showed that treatment with ethyl eicosapentaenoate markedly reduced the occurrence of coronary artery disease in patients with PAD [12]. It is supposed that administration of highly purified ethyl eicosapentaenoate is beneficial in patients with T2DM who have PAD.

In conclusion, highly purified ethyl eicosapentaenoate improves peripheral microcirculation in the toes of patients with T2DM who have decreased TBI, independently of glycemic control and blood pressure. Administration of highly purified ethyl eicosapentaenoate is beneficial in preventing the development of gangrene and avoiding amputation because of gangrene in patients with T2DM who have PAD.

References

8. Carter SA. Role of pressure measurements in vascular disease. In:
Highly Purified Eicosapentaenoic Acid Improves Decreased Toe-Brachial Index in Japanese Patients with Type 2 Diabetes Mellitus


